The Australian Diabetes Society is strongly committed to its goals and objectives in recognising the importance of its members and advocating for better support in diabetes research, treatment and care. The ADS is very proud to offer a number of Awards, Research Grants and Fellowships each year. Call for applications/nominations is from March to October and some recipients of these awards, grants and fellowship are expected to present their project research findings at the following Australasian Diabetes Congress.
The awards, grants and fellowships are reviewed by an independent committee of both ADS members and external reviewers. To apply for any of the ADS awards, grants and fellowships; the applicant/nominee must be a financial member of the society for at least one year at the time of application.
Please refer to the tabs below for more information on the eligibility criteria for each award, grant and fellowship.
2024 ADS Kellion Award
2024 ADS Kellion Award
The Australian Diabetes Society and Diabetes Australia invite applications for the Award for an Australian who has demonstrated innovative leadership and has made an outstanding and highly original contribution to the advancement of knowledge in diabetes research, clinical or service areas in Australia. This is an annual award that commenced in the year 2000 and is the premier award bestowed on an individual by the Australian Diabetes Society. Nominations are now called for this Award which will be considered by a review committee consisting of the Australian Diabetes Society Council as well as prominent Australian diabetes experts and if appropriate international referees.
Nominations may be self-initiated, initiated by colleagues or by organisations. The recipient of the ADS Kellion Award must be a financial ADS member (paid subscription for 2024) and a member of the society for at least 12 months at time of nomination. The recipient will be required to deliver the ADS Kellion Plenary Lecture at the 2024 Australasian Diabetes Congress (ADC) that will be held at the Perth Convention and Exhibition Centre in WA from Wednesday 21st to Friday 23rd August 2024. The Award will include a return business class airfare to the congress, accommodation for the duration of the meeting, full ADC registration, and a commemorative plaque. The award also includes a $10,000 honorarium.
Nominations should include a letter (not exceeding 2 pages) clearly stating the basis of the nomination and a full curriculum vitae of the nominee. Nominations made in the previous years have been retained and will be considered also.
2024 ADS Kellion Award nominations have now closed.
Nominations Closing Date: Monday, 29 April 2024 – CLOSED
Please forward further enquires to:
Dr Sof Andrikopoulos
Chief Executive Officer
Australian Diabetes Society
Email: ceo@diabetessociety.com.au
Previous recipients of this prestigious award include: Glynis Ross (2024), Karin Jandeleit-Dahm (2023), Sophia Zoungas (2022), Stephen Twigg (2021), Thomas Kay (2020), Alicia Jenkins (2019), Jonathan Shaw (2018), Mark Febbraio (2017), Kerin O’Dea (2016), Stephen Colagiuri (2015), Timothy Davis (2014), Peter Colman (2013), Joseph Proietto (2012), Frank Alford (2011), Dennis Yue (2010), Michael Horowitz (2009), Martin Silink (2008), Ted Kraegen (2007), David James (2006), Mark Cooper (2005), Tim Welborn (2004), Paul Zimmet (2003), George Jerums (2002), Don Chisholm (2001), Len Harrison (2000)
2024 ADS Ranji and Amara Wikramanayake Clinical Diabetes Research Award
2024 ADS Ranji and Amara Wikramanayake Clinical Diabetes Research Award
This Mid-Career Award supporting the career of a clinical diabetes researcher has been made possible by the generosity of Dr Ranji Wikramanayake, a long-standing member of the Australian Diabetes Society. The Australian Diabetes Society invites applications for a Mid-Career Diabetes Research Award from endocrinology/diabetes clinicians who are members of the Australian Diabetes Society (ADS) and are up to 20 years’ post-doctoral degree or equivalent. Applications can be nominated by financial members of the ADS or by self-nomination. The award is to recognise significant contributions to diabetes research by a clinician and to support further advancement of those achievements. The successful candidate will deliver the ADS Ranji and Amara Wikramanayake Clinical Diabetes Award Lecture at the 2024 Australasian Diabetes Congress that will be held at the Perth Convention and Exhibition Centre in WA from Wednesday 21st to Friday 23rd August 2024. In addition, the awardee will be required to provide a written report on their further achievements (projects, presentations, publications, funding, community engagement) within 18 months of accepting the award. The award is for $40,000 together with a commemorative plaque.
To be eligible for this award, applicant must be:
- A financial member of ADS (paid subscription for 2024) for at least 12 months at time of application and who has provided significant contributions to clinical diabetes research
- Up to 20 years post-doctoral degree or equivalent e.g FRACP
- Australian-based
- Provide a 1-page overview of how the award funds will further assist their ongoing clinical diabetes research
- Available to present the award lecture at the Australasian Diabetes Congress in 2024 in person.
Applications, accompanied by a full curriculum vitae, are now invited and should be in the form of a letter not exceeding 2 pages outlining the applicant’s suitability for the award and a 1 page overview of how the award funds will further assist their ongoing clinical diabetes research. Enquiries should be emailed to Dr Sof Andrikopoulos, ADS CEO at ceo@diabetessociety.com.au. Previous recipients are ineligible to re-apply for this award.
2024 ADS Ranji and Amara Wikramanayake Clinical Diabetes Research Award applications have now closed.
Applications Closing Date: Monday, 6 May 2024 – CLOSED
2024 ADS Australasian Diabetes Congress Awards
2024 ADS Australasian Diabetes Congress Awards
A number of awards and grants are available for ADS members attending the 2024 Australasian Diabetes Congress that will be held at the Perth Convention and Exhibition Centre in WA from Wednesday 21st to Friday 23rd August 2024. Please see below for all ADS ADC Awards and Grants on offer for 2024:
ADS Poster Awards
ADS Poster Awards for both Discovery Science and Clinical Research will be on offer during the 2024 ADS/ADEA Australasian Diabetes Congress. ADS Poster Awards are to the value of $500 each.
Eligibility is as follows:
- A financial member of the ADS (paid subscription for 2024)
- Applicants must be an early career researcher
- You must be available to present at the time of the poster session
- Each applicant must provide a supporting statement including one signed by his/her supervisor or department head, indicating that the work presented is substantially the candidate’s own work
- Previous winners of this award are in-eligible to apply
Please ensure that you have uploaded your supporting documentation. Please contact Linda Valenzisi from the ADS Secretariat for any further information by email to linda@diabetessociety.com.au.
- 2024 ADS ADC Awards applications have now closed.
Applications Closing Date: Monday, 20 May 2024 – CLOSED
ADS Pincus Taft Young Investigator Award
The ADS-Pincus Taft Young Investigator Award is to the value of $2000. The finalists will be categorised into Discovery Science and the award will be given to the best oral presentation by a junior ADS member at the Australasian Diabetes Congress as judged by peer review and a committee appointed by the ADS Council.
Eligibility is as follows:
- A financial member of the ADS for 12 months at the time of application
(Member must have joined as a member of ADS no later than May 2023 and paid subscription for 2024) - Applicants must not be more than 2 years beyond the award of a doctoral degree (PhD, MD) or fellowship (FRACP)
- Each applicant must provide a supporting statement including one signed by his/her supervisor or department head, indicating that the work presented is substantially the candidate’s own work
- Previous winners of this award are in-eligible to apply
- Finalist applicants must present work of abstract submitted for the conference; if not they will be in-eligible to receive the award 6-8 applicants will be selected from abstracts to present in the ADS-Pincus Taft Young Investigators Session.
Please ensure that you have uploaded your supporting documentation. Please contact Linda Valenzisi from the ADS Secretariat for any further information by email to linda@diabetessociety.com.au
- 2024 ADS ADC Awards applications have now closed.
Applications Closing Date: Monday, 20 May 2024 – CLOSED
ADS President’s Young Investigator Award
The ADS President’s Young Investigator Award is to the value of $2000. The finalists will be categorised into Clinical Research and the award will be given to the best oral presentation by a junior ADS member at the Australasian Diabetes Congress as judged by peer review and a committee appointed by the ADS Council.
Eligibility is as follows:
- A financial member of the ADS for 12 months at the time of application
(Member must have joined as a member of ADS no later than May 2023 and paid subscription for 2024) - Applicants must not be more than 2 years beyond the award of a doctoral degree (PhD, MD) or fellowship (FRACP)
- Each applicant must provide a supporting statement including one signed by his/her supervisor or department head, indicating that the work presented is substantially the candidate’s own work
- Previous winners of this award are in-eligible to apply
- Finalist applicants must present work of abstract submitted for the conference; if not they will be in-eligible to receive the award 6-8 applicants will be selected from abstracts to present in the ADS Presidents Young Investigators Session.
Please ensure that you have uploaded your supporting documentation. Please contact Linda Valenzisi from the ADS Secretariat for any further information by email to linda@diabetessociety.com.au
- 2024 ADS ADC Awards applications have now closed.
Applications Closing Date: Monday, 20 May 2024 – CLOSED
2024 Best ADS Clinical Presentation Award in memory of Dr Paul Lee
2024 Best ADS Clinical Presentation Award in memory of Dr Paul Lee
The Best ADS Clinical Presentation Award in memory of Dr Paul Lee is to the value of $1,250. The finalists will be categorised into Clinical Research and the award will be given to the best oral presentation by an ADS member at the 2024 Australasian Diabetes Congress that will be held at the Perth Convention and Exhibition Centre in WA from Wednesday 21st to Friday 23rd August 2024 and judged by peer review and a committee appointed by the ADS Council. 2019 was the inaugural year of this annual award.
Eligibility is as follows:
- A financial member of the ADS for 12 months at the time of application
(Member must have joined as a member of ADS no later than May 2023 and paid subscription for 2024) - Applicants must be a mid-career clinical researcher (4-10 years post-doctoral)
- Each applicant must provide a supporting statement indicating that the work presented is substantially their own work
- 6-8 applicants will be selected from the submitted abstracts to present in the award session
- Previous winners of this award are in-eligible to apply
- Finalist applicants must present work of abstract submitted for the conference; if not they will be in-eligible to receive the award
Please ensure that you have uploaded your supporting documentation. Please contact Linda Valenzisi from the ADS Secretariat for any further information by email to linda@diabetessociety.com.au
- 2024 ADS ADC Awards applications have now closed.
Applications Closing Date: Monday, 20 May 2024 – CLOSED
2024 ADS Jeff Flack Diabetes Data Award
2024 ADS Jeff Flack Diabetes Data Award
The Australian Diabetes Society invites nominations for the 2024 ADS Jeff Flack Diabetes Data Award for an Australian researcher who has made an outstanding contribution to Diabetes data collection in Australia. The Award will be considered by a review committee consisting of prominent Australian diabetes researchers with the option to co-opt international referees. The nominee must be a financial member of the ADS (paid subscription for 2024) and have been a member for at least 12 months at the time of their nomination for this award. At least one of the Nominator/s must be an ADS member and nominations can be self-initiated or initiated by colleagues. The award will include a $5,000 honorarium together with a commemorative plaque.
Categories of merit include:
- Multiple / Significant / Substantial Publications (or In Press) involving data collection, collation, analysis and reporting (beyond ‘routine day-to-day’ minimum dataset collection);
- Something ‘Novel’ regarding data collection / reporting – development of data systems;
- Substantial contribution to data issues (attendance / chair of Committee(s) on data issues – developing standards etc);
- List the best 5 or 10 relevant publications;
- Highlight all relevant publications in your CV.
Nominations should include a letter (not exceeding 2 pages) clearly stating the basis of the nomination and a full curriculum vitae.
Further enquiries can be directed to Dr Sof Andrikopoulos, ADS CEO, via email at ceo@diabetessociety.com.au
2024 ADS Jeff Flack Diabetes Data Award nominations have now closed.
Nominations Closing Date: Monday, 27 May 2024 – CLOSED
2024 ADS Lifetime Achievement Award
2024 ADS Lifetime Achievement Award
The Australian Diabetes Society invites nominations for the 2024 ADS Lifetime Achievement Award.
Eligibility:
The Lifetime Achievement Award recognises an individual who has:
- An established history of distinguished service to education, clinical practice and/or research and training in diabetes
- Made a lasting contribution to diabetes
- Exhibited leadership and mentorship in diabetes research and/or clinical practice on a state, national and/or international level
Selection of the nominee is made on the basis of the candidate’s significant, fundamental contributions to diabetes (whether in research, clinical practice, leadership, mentorship or other); the lasting impact of these contributions to the sector; and the demonstration of a lifetime commitment to diabetes.
Nominees must have:
- Made a positive impact to diabetes [at either state/territory or national level]
- The respect of professional peers
- General acknowledgement as having reached a pinnacle of their profession
- Demonstrated, over an extended period of time, a contribution which has included either research and/or clinical practice, professional leadership and service to the diabetes community
- Held positions of leadership
- Personal integrity
- On-going membership with the ADS
Nominees awarded the 2024 ADS Lifetime Achievement Award will be announced at the 2024 ADS Annual General Meeting.
Please submit two letters of recommendation including a full curriculum vitae of the nominee. One letter of recommendation must be by a financial member of the ADS (paid subscription for 2024).
2024 ADS Lifetime Achievement Award nominations have now closed.
Nominations Closing Date: Monday, 17 June 2024 – CLOSED
RACP Australian Diabetes Society Research Establishment Fellowship for 2025
RACP Australian Diabetes Society Research Establishment Fellowship
The Royal Australasian College of Physicians (RACP) and the Australian Diabetes Society (ADS) are pleased to invite applications for the 2025 RACP Australian Diabetes Society Research Establishment Fellowship.
Eligibility criteria is as follows:
Purpose: To assist a current or future RACP Fellow in establishing a career in diabetes research. Research may relate to any form of diabetes and be from any domain, including basic, clinical, epidemiological, health services or translational research.
Value: Up to $50,000 for 1 year.
Eligibility: Australian Fellows or Advanced Trainees of the RACP’s Divisions, Faculties and Chapters, who are current financial members of the Australian Diabetes Society for at least 12 months prior to the submission date.
Tenable: Australia only.
Special requirements: Recipients must present their research findings at the Australasian Diabetes Congress within 2 years.
The Fellowship is made available by a grant from the Australian Diabetes Society, matched with funds provided by members of the RACP.
2025 RACP Australian Diabetes Society Research Establishment Fellowship applications have now closed.
Applications Closing Date: Tuesday, 9 July 2024 – CLOSED
For further information please visit the RACP website at Research Establishment Fellowships (racp.edu.au)
2024 ADS Australasian Diabetes Congress Travel Grants
2024 ADS Australasian Diabetes Congress Travel Grants
This year a number of ADS Travel Grants will be awarded to junior investigators who have an abstract accepted for presentation at the 2024 Australasian Diabetes Congress that will be held at the Perth Convention and Exhibition Centre in WA from Wednesday 21st to Friday 23rd August 2024. The number and size of grants will be determined according to the number and suitability of applications and the funds available. The travel grants will provide a significant contribution to the individuals travel costs to attend the congress. Applications will be prioritised using abstract review scores.
Eligibility is as follows:
- A financial member of the ADS for 12 months at the time of application
(Applicant must have joined as a member of ADS no later than July 2023 and paid subscription to 30 June 2025 with no outstanding arrears at the time of application) - In training for a higher degree e.g. PhD, MD, fellowship or medical specialty
- Supported by a statement from the candidate’s supervisor or department head indicating the nature of their present position and the availability of other sources of financial support for their registration to the congress
- Travel Grants will be made directly to the member and not their respective institution
- Applicant must be the presenting author and abstracts must be submitted and accepted for sessions within the ADS program only (clinical or discovery science)
- Applicant must not live within the local city of where the ADC is being hosted e.g. Perth
- Applicant must attend the ADC in person and present their abstract
Note: Applicants must not be in receipt of a grant from any other body to attend the ADS/ADEA Australasian Diabetes Congress or a meeting in association with the ADS/ADEA ADC.
Please ensure that you upload your supporting documentation. The successful applicants will be advised in writing one week prior to the congress and travel grants will be paid following the ADC. Please contact Linda Valenzisi from the ADS Secretariat for any further information by email to linda@diabetessociety.com.au
- 2024 ADS ADC Travel Grant applications have now closed.
Applications Closing Date: Monday, 15 July 2024 – CLOSED
2024 ADS Lindsey Baudinet Rising Star Award in Type 1 Diabetes Research
2024 ADS Lindsey Baudinet Rising Star Award in Type 1 Diabetes Research
The Australian Diabetes Society together with the Lindsey Baudinet Family is pleased to announce the 2024 ADS Lindsey Baudinet Rising Star Award in Type 1 Diabetes Research. The purpose of the award is to support eligible early-career researchers to pursue research in type 1 diabetes and its complications. The award is $20,000 for one year.
To be eligible for this award, you need to:
- Be a financial member of ADS (paid subscription for 2024) for at least 12 months at the time of application
- Be Australian-based
- Be no more than 10 years post-doctoral at the time of application
- Be with a mentor or in a research group/department/institute with a proven track record of supporting emerging researchers for success.
- Be undertaking clinical or preclinical research in type 1 diabetes and its complications
- Be an outstanding early-career researcher
- Previous recipients are ineligible to re-apply for this award.
The selection committee will assess applicants based on:
- Project proposal
- CV
- Referee reports
- Demonstrated research excellence
- Demonstrated financial need
- Career aspiration
2024 ADS Lindsey Baudinet Rising Star Award in Type 1 Diabetes Research applications have now closed.
Applications Closing Date: Monday, 10 June 2024 – CLOSED
Diabetes Australia Research Program Grants for 2025
Diabetes Australia Research Program Grants for 2025
Diabetes Australia is dedicated to reducing the incidence and impact of diabetes on people, health systems and society. We work with people living with or at risk of diabetes, their families and carers, health professionals, researchers, funders, other diabetes organisations and the community to positively change people’s lives.
In 2025, Diabetes Australia will provide vital funding for diabetes research projects across Australia, including:
- A limited number of General Grants for 2025 that will be offered to 2024 General Grant Applicants that attained a fundable score following a rigorous competitive peer-review process conducted in late 2023.
- A new category of Grants – Diabetes Community Priority Grants. Four Grants of up to $100,000 each. Further details on how to apply will be announced in the week of World Diabetes Day.
- Two $150,000 Millennium Awards: one for type 1 diabetes and one for type 2 diabetes. Applications closed 31 July 2024 – CLOSED.
- One $150,000 Charles Campbell Coghlan OAM Emerging Researcher Award for an early to mid-career researcher. Applications close 31 July 2024 – CLOSED.
Applications for the 2025 Millennium and Coghlan Awards have now closed. More details to come for the 2025 Diabetes Community Priority Grants.
Application forms and further information are available at www.diabetesaustralia.com.au/diabetes-australia-research-program (Please click here to download the flyer)
Applications Closing Date for Millennium and Coghlan Awards: Wednesday, 31 July 2024 – CLOSED
The Australian Diabetes Society is proud to support a general grant to the value of $60,000 towards DARP.
2024 ADS-AstraZeneca Diabetes Research Grant
2024 ADS-AstraZeneca Diabetes Research Grant
One grant will be offered and up to the value of $20,000. This grant has been made possible through the generosity of AstraZeneca who have strongly supported diabetes research over many years.
Grant proposals must involve improvement of patient care and be consistent with the following identified national diabetes priorities to:
- Reduce the prevalence and incidence of people developing type 2 diabetes
- Promote earlier detection of diabetes
- Reduce the occurrence of diabetes-related complications (e.g. chronic kidney disease and heart failure) and improve quality of life among people with diabetes
- Reduce the impact of diabetes in Aboriginal and Torres Strait Islander peoples and other high risk groups
- Strengthen prevention and care through research, evidence and data.
Projects must be applicable to diabetes care in Australia. The Principal Investigator must be a financial member (paid subscription to 30 June 2025) of the ADS for at least one year at the time of application. Grant applications are to be submitted in the format: title, background, aims, methods, expected contribution to patient care, project plan, ethics approval (if relevant) and a detailed budget. Grant applications must be NO longer than four A4 pages with a minimum font size of 12 (includes references). Applications must be accompanied by a full curriculum vitae. A brief report on the outcome of the work must be submitted to ADS and the awardee is expected to present their work at the 2026 Australasian Diabetes Congress and must include acknowledgement of the Australian Diabetes Society and AstraZeneca of the grant support.
Please note: Only one grant application is permitted per applicant. All applications will be screened by the Grant Review Committee which will comprise members of the Australian Diabetes Society Council and external reviewers. The Grant Review Committee reserves the right to reject any application prior to review if it does not comply with the criteria or the purpose of this grant scheme. There will be no feedback provided to unsuccessful applications. Previous recipients of the ADS-AstraZeneca Diabetes Research Grants are ineligible to re-apply.
2024 ADS-AstraZeneca Diabetes Research Grant applications have now closed.
Applications Closing Date: Monday, 28 October 2024 – CLOSED
2025 ADS-Skip Martin Early Career Fellowship
2025 ADS-Skip Martin Early Career Fellowship
Fellowship Amount: $80,000 for one year plus a travel/conference allowance of up to $5,000.
Eligibility Criteria is as follows:
- Applicant must be a financial ADS member (Paid membership to 30 June 2025) for at least one year at the time of application
- The fellowship must commence by 30 June, 2025
- The applicant must be less than 6 years post-doc as of December, 2024 (excluding career disruptions)
- Applicant must provide a statement that the fellowship is for salary support and is not for support towards a grant/consumables.
- Applicant must notify ADS of any fellowship applications currently pending (e.g. NHMRC)
- The fellow must take up a position in Australia for the duration of the award
- The project must be diabetes related
- Previous recipients of this fellowship are ineligible to re-apply
Conditions of the Fellowship include the following:
- Award of PhD is not required at the time of application but a PhD must be awarded by the time of commencement
- The award cannot be held in conjunction with another major fellowship. If the highest ranking applicant is successful with another fellowship application or grant providing salary support, they must notify ADS and the next suitable candidate will be offered the award
- ADS reserves the right to not award the fellowship if there is no eligible applicant of sufficiently high standard
- The fellow must present their work at the 2026 Australasian Diabetes Congress
- The fellow must acknowledge the Australian Diabetes Society in publications related to the work
- At the conclusion of the research project, the applicant must provide a report of 1-2 A4 pages outlining the outcomes of the project
2025 ADS-Skip Martin Early Career Fellowship applications have now closed.
Applications Closing Date: Monday, 4 November 2024 – CLOSED
ADS-Abbott Travel Grants to ADA
ADS-Abbott Travel Grants to ADA
The Australian Diabetes Society is pleased to call for applications for the 2019 ADS-Abbott Travel Grants to attend the American Diabetes Association meeting to be held in San Francisco, California, USA from 7-11 June 2019. The merit-based travel grant will be up to the value of A$2,000 and awarded to PhD student applicants.
To be eligible, applicants must:
- Be a financial member of the ADS (Paid 2019) for 12 months at the time of application
- Be presenting at ADA in San Francisco (poster or oral)
- Be a PhD or Masters student, or <1 year from submitting their PhD. Preference will be given to current students. Please include commencement date and planned thesis submission date
- Agree to provide a written report within 2 months of the meeting for the ADS newsletter
- Acknowledge the travel grant in their presentation
To apply, please submit:
- A 1-page cover letter describing what benefit you expect to obtain from the meeting, and any other associated lab / other scientific visits
- A letter of support from your supervisor
- A short CV (maximum of 4 pages), in 12 point font, including qualifications, publications, and presentations
- A copy of your abstract
- A copy of the acceptance from the ADA
- A budget, including receipts where available, and
- A statement including ALL other sources of support and ALL other sources of pending support for attending the meeting.
The travel grant applications should be directed to Dr Sof Andrikopoulos, CEO at the Australian Diabetes Society on email ceo@diabetessociety.com.au and include the grant name in the subject line of the email.
Applications will be peer-reviewed. The travel grant is merit based, and we reserve the right not to award the funds in this round if there are no qualifying applicants of suitable calibre. The ADS is very grateful to Abbott Australasia for providing support of the travel grant to ADS members.
Applications Closing Date: Applications have now closed
For further information, please contact the ADS Secretariat via email at ads@diabetessociety.com.au